STANDARD TREATMENT VS
PRECISION ONCOLOGY
Understand the fundamental differences between traditional one-size-fits-all protocols and biomarker-driven personalized cancer medicine.
Two Paradigms of Cancer Treatment
Standard oncology treats cancer based on tumor location and stage using established protocols. Precision oncology adds a layer: molecular profiling reveals the genetic drivers of each patient's tumor, enabling therapies that target those specific vulnerabilities.
โPrecision oncology asks not just "where is the cancer?" but "what drives this cancer at the molecular level?"โ
Standard Treatment vs Precision Oncology
Precision Oncology
- Biomarker-driven drug selectionTreatment matched to tumor genetics (HER2, EGFR, ALK, BRAF).
- Higher response rates in selected patientsTargeted therapies achieve 40-80% ORR in biomarker-positive tumors.
- Fewer off-target side effectsDrugs designed to hit tumor-specific pathways.
- Requires genomic testing (NGS)Adds 1-3 weeks and $2,000-$5,000 for comprehensive panels.
Standard Treatment
- Protocol-based drug selectionTreatment based on cancer type, stage, and histology.
- Proven across large populationsDecades of clinical trial data and established guidelines.
- More systemic side effectsChemotherapy affects all rapidly dividing cells.
- Faster treatment initiationNo molecular profiling delay; standard labs suffice.
Detailed Comparison
| Aspect | Standard Treatment | Precision Oncology |
|---|---|---|
| Treatment selection | Cancer type + stage | Cancer type + stage + biomarkers |
| Diagnostic requirement | Biopsy, imaging, basic labs | NGS panel, IHC, FISH, ctDNA |
| Time to start treatment | 1-2 weeks | 2-4 weeks (includes profiling) |
| Response rate | 20-40% (unselected) | 40-80% (biomarker-selected) |
| Side effect profile | Broad systemic toxicity | Targeted; fewer off-target effects |
| Cost per line | $5,000-$30,000 | $15,000-$100,000+ |
| Insurance coverage | Standard coverage | Variable; depends on biomarker/drug |
When Is Precision Oncology Recommended?
Precision approaches are most valuable when standard options are limited or molecular targets exist.
Non-Small Cell Lung Cancer
EGFR, ALK, ROS1, BRAF, KRAS G12C, MET, RET, NTRK testing is standard of care at diagnosis.
Breast Cancer
HER2, ER/PR, PIK3CA, BRCA1/2 testing guides therapy selection across all stages.
Colorectal Cancer
RAS/BRAF testing, MSI status, and HER2 amplification determine treatment strategy.
Rare or Refractory Tumors
Comprehensive genomic profiling (CGP) may identify actionable targets when standard options fail.
Frequently Asked Questions
About Precision Oncology
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination โ travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Wondering If Precision Oncology Is Right for You?
Upload your reports and our team will assess whether genomic profiling could identify better treatment options for your cancer.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified oncologist before making treatment decisions.